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Abstract. The POS-1 murine model of osteolytic osteosarcoma
was used to elucidate the molecular and cellular mechanisms
involved in the development of primary bone tumors and
associated lung metastasis. The POS-1 cell line is derived
from an osteosarcoma tumor which develops spontaneously
in C3H mice. The POS-1 cell line was characterized in vitro
by mineralization capacity and expression of bone markers
by semi-quantitative RT-PCR, compared to primary osteoblasts
and bone marrow cells. POS-1 cells showed no mineral-
ization capacity and exhibited an undifferentiated phenotype,
expressing both osteoblastic and unexpected osteoclastic
markers (TRAP, cathepsin K and RANK). Thereby, experi-
ments were performed to determine whether RANK was
functional, by studying the biological activity of murine
RANKL through the receptor RANK expressed on POS-1
cells. Results revealed a RANKL-induced increase in ERK
phosphorylation, as well as BMP-2 induction at the mRNA
and protein levels, and a decrease of POS-1 cell proliferation
in the presence of 10 ng/ml RANKL. BMP-2 induction is
dependent on the ERK 1/2 signal transduction pathway, as its
expression is abolished in the presence of UO126, a specific
synthetic inhibitor of the ERK 1/2 pathway. Moreover, a 2-fold
molar excess of soluble RANK blocks the RANKL-induced
BMP-2 expression, demonstrating that the biological effects
of RANKL observed in POS-1 cells are mediated by RANK.
This is the first report describing a functional RANK expressed
on osteosarcoma cells, as shown by its ability to induce signal
transduction pathways and biological activity when stimulated
by RANKL.
Introduction
Osteosarcomas (OS), the most frequent primary bone tumor
that develops mainly in the young, the median age of diagnosis
being 18 years, are classified into several subgroups according
to their localisation and histology (1). The unifying histological
feature present in all types and subtypes of OS is the presence
of osteoid produced by neoplastic cells (2). The origin of
osteosarcoma is not fully understood, as the tumor cells may
have different origins depending on the dominant histological
element. A preference for pulmonary metastases compared
with other metastatic sites is a distinct feature of osteosarcoma,
and 5-year survival rates after the detection of lung metastasis
are less than 30% (3). Despite recent improvements in
chemotherapy and surgery, the problem of non-response to
chemotherapy remains and current strategies for the treatment
of high-grade osteosarcoma fail to advance in its prognosis.
Therefore, the developments of new therapies are needed. 
Osteoprotegerin (OPG), the receptor activator of NF-κB
(RANK) and RANK ligand (RANKL) are the main molecules
involved in the regulation of bone metabolism (reviewed in
ref. 4). In the case of bone tumors, Grimaud et al demonstrated
an increase in the RANKL:OPG ratio in the serum of patients
with high-grade osteosarcoma (5), suggesting that the
molecular triad, OPG/RANK/RANKL, might play a crucial
role in tumorigenic osteolysis. RANKL augmentation directly
produced by tumor cells (6) or indirectly via osteoblasts (7)
contributes not only to an increased bone resorption but also
to the release of growth factors stored in the bone matrix,
creating a suitable context for tumor expansion as they
increase tumor cell proliferation (8). In addition, it has been
reported that tumor cell proliferation is often followed by a
loss of differentiation markers or adhesion molecules, such as
integrins, allowing the spreading of tumor cells to other
organs leading to metastasis (9).
To elucidate the molecular and cellular mechanisms
involved in the development of primary bone tumors and
associated lung metastasis, the POS-1 murine model of
osteosarcoma was used. The POS-1 cell line is derived from
osteosarcoma which developed spontaneously in C3H mice.
The tumor can be successfully transplanted in C3H mice or
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POS-1 cells inoculated into the hind footpad of mice and
shows spontaneous metastasis to the lungs (10). Tumors were
first recognized macroscopically at 2 weeks after inoculation
and developed in more than 90% of inoculated mice at 5 weeks,
lung metastasis being observed in all mice that developed
tumors.
In this study, the in vitro phenotype of the POS-1 cell line
was compared to those of the primary murine osteoblasts and
bone marrow cells, in terms of mineralization capacity and
bone marker expression. POS-1 cells exhibit an undifferentiated
phenotype as they express osteoblastic and surprisingly
osteoclastic markers, such as tartrate resistant acid phos-
phatase (TRAP), cathepsin K (Cat K) and RANK. Data from
the literature reported the involvement of RANKL, either
directly expressed by tumor cells themselves (6) or indirectly
by osteoblasts or bone stromal cells (7), in bone tumor
progression. In the osteolytic tumor-bone ‘vicious cycle’
described for bone metastasis from breast carcinoma (8),
RANKL may mediate the release of growth factors from
bone matrix and the production of growth factors, cytokines
or chemokines by the activated osteoclast, or it may directly
induce the production of angiogenic, invasion, chemoattractant
and osteotropic factors by RANK positive cells. The influence
of murine RANKL was therefore determined to see whether
RANK may act as a functional receptor at the surface of
osteosarcoma cells. The potential biological activity of
RANKL was assayed on POS-1 cells in terms of phenotype
modulation, signalling pathway and cell proliferation. 
Materials and methods
Cell culture. The murine osteosarcoma cell line, POS-1,
derived from osteosarcoma which spontaneously developed
in mice was kindly provided by the Kanagawa Cancer Center
(Kanagawa, Japan). The cells were cultured in RPMI-1640
medium (Bio Whittaker, Verviers, Belgium) supplemented
with 10% fetal bovine serum (FBS, Dominique Dutscher,
Brumath, France), at 37˚C in a humidified atmosphere (5%
CO2/95% air). The cells were harvested at confluence with
trypsin (0.5 g/l)/EDTA (0.2 g/l) (Cambrex BioSciences,
Verviers, Belgium). Mouse macrophage precursors RAW
264.7 cells (obtained from Professor Matsumoto, Japan) were
used as osteoclast-like cells as they are able to differentiate
into multinucleated cells in the presence of RANKL (11).
Bone marrow cells (BMC) and primary osteoblasts were
isolated from C3H/HeN mice (IFFA-CREDO, L'Arbresles,
France). Briefly, femora and tibiae were collected and
minced in RPMI-1640 after the removal of soft tissue. Bone
fragments were cultured as explants in one side, whereas
bone marrow was cultured separately, to lead respectively to
osteoblasts and bone marrow cell cultures, both cell types
being cultured in RPMI-1640 medium supplemented with
10% FBS and antibiotics, at 37˚C in a humidified atmosphere.
RNA extraction and semi-quantitative RT-PCR analysis.
POS-1 cells and osteoblasts were seeded in a 6-well plate at a
density of 104 cells/cm2 in RPMI-1640 supplemented with
10% FBS. RAW 264.7 cells were seeded at the same density
and maintained in phenol red-free ·-MEM supplemented 1%
nonessential amino acids and 10% FBS. At confluence, total
RNA was isolated from POS-1 cells, primary osteoblasts and
the differentiated RAW 264.7 cells using TRIzol reagent
(Invitrogen, Eragny, France). Total RNA were quantified by
measuring the OD260 and integrity was checked by 1%
agarose/formaldehyde gel electrophoresis. First, RNA was
reversed-transcribed (RT), using 400 U MMLV-RT from
Invitrogen. To determine the expression of OPG, RANKL,
collagen I (Coll I), osteocalcin (OC), Bone Sialo-Protein
(BSP), bone morphogenetic protein-2 (BMP-2), core binding
factor 1 (Cbfa1), RANK, calcitonin receptor (CTR), tartrate
resistant acid phosphatase (TRAP) and cathepsin K (Cat K),
two microliters of the RT reaction mixture were subjected to
PCR using upstream and downstream primers (30 pmoles
each, Table I) and 0.25 μl of 5 U/μl Taq polymerase (Eurobio,
Les Ulis, France). After the number of PCR cycles was
increased, a plot was made for each sample, and the cycle
values corresponding to the linear part of the amplification
curve were determined (30 cycles for all primers, except 40
for CTR) and used to quantify the messages versus the 18S
signal determined in the same way (27 cycles). The PCR
products were electrophoresed in 1% agarose gel containing
ethidium bromide. The band densities were measured using
the ImageQuant computer software program (Molecular
Dynamics). The relative expression of each gene was calculated
as the ratio to 18S signal. Three independent experiments
were performed for each gene and a representative experiment
is shown in the Results section. To study the influence of
RANKL on the POS-1 phenotype, mRNA expression was
quantified in RANKL-treated POS-1 cells. When cells reached
70-80% confluence, they were washed and cultured in serum-
free RPMI for 6 to 24 h in the presence of 1-200 ng/ml human
soluble RANKL, kindly provided by Amgen Inc. (Thousand
Oaks, USA). In a separate experiment, POS-1 cells were
treated for 6 h with 100 ng/ml human RANKL preincubated
for 1 h at room temperature with increasing concentrations of
soluble human RANK (100-400 ng/ml, R&D Systems).
Cell proliferation assays. POS-1 cells were seeded in a 96-
well-plate at a density of 2,800 cells per well, and cultured
for 72 h in RPMI-1640 medium supplemented with 0.5% heat
inactivated serum in the absence or presence of 1-200 ng/ml
human soluble RANKL, or 1-100 ng/ml hBMP-2 (Abcys, Paris,
France). The cell proliferation was determined by an XTT-
based method, using the Cell Proliferation Kit II (Sigma,
St. Quentin Fallavier, France) according to the supplier's
recommendations. The OD was finally determined at 450 nm
using a Wallac 1420 VICTOR 2™ multilabel counter (Perkin-
Elmer, USA).
Mineralization assay. Mineralization assays were performed
as previously described (12). Briefly, bone marrow cells and
POS-1 cells were seeded in a 6-well plate at a density of
104 cells/well, in RPMI-1640 medium supplemented with
10% FBS, in the absence or presence of 50 μg/ml ascorbic
acid (Sigma) and 10-8 M dexamethasone (Sigma). The medium
was changed twice a week. After 7 days in culture, 10 mM of
Na-ß-glycerophosphate (Sigma) was added to each well in
association with ascorbic acid and dexamethasone, and
maintained in culture for 14 days. At the end of the incubation
period, supernatant was removed and ice-cold ethanol was
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added to the wells for 1 h. The cells were then washed twice
with distilled water, and the presence of mineralized nodes
was revealed by microscopic observation (Leica, DM IRB)
using a 40 mM alizarin red staining solution, pH 7.4. In a
separate experiment, POS-1 cells were co-cultured with bone
marrow under the same experimental conditions to determine
whether POS-1 cells could interfere with the mineralization
capacity of bone marrow cells.
Protein quantification and alkaline phosphatase assays.
POS-1 cells were seeded in a 6-well plate at a density of
104 cells/well and cultured as described above (§ Cell culture).
After 96 h of culture, POS-1 cells were washed with PBS and
lysed in ice-cold buffer [NaCl 150 mM, Tris 50 mM, Nonidet
P-40 1%, sodium deoxycholate 0.25%, NaF 1 mM, leupeptine
10 mg/ml, aprotinin 10 mg/ml, phenymethylsulfonylfluoride
(PMSF) 0.5 mM, and glycerol 10%]. The total amount of
proteins for each sample was determined using a bicinchominic
acid (BCA, Sigma) based method. Ten microliters of cellular
lysis or standard BSA solution were added to 200 μl of
reagent (Copper II solution 1/50 diluted in bicinchominic
acid) and incubated for 30 min at 37˚C. OD was determined
at 570 nm as well as the protein concentration compared to
the standard curve. The same amounts of proteins were used
to perform alkaline phosphatase assays using Enzyline PAL
kit according to the supplier's recommendations (BioMérieux,
Marcy l'Etoile, France). At the end of the incubation period
(10 min at room temperature), the reaction was stopped and
OD was determined at 405 nm using a Wallac 1420 VICTOR
2™ multilabel counter.
Signal transduction analysis by Western blotting. POS-1
cells were seeded at a density of 105 cells/well in a 6-well
plate in RPMI-1640 supplemented with 10% FBS. When
POS-1 cells reached 70-80% confluence, they were washed 3
times with RMPI-1640 and cultured in serum-free RMPI-1640
for 24 h, then incubated for 1, 2, 5, 10, 15 and 30 min in the
absence or presence of 100 ng/ml human RANKL. POS-1
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Table I. Oligonucleotide primers used for RT-PCR.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Molecule Primers Strand Size (bp) Conditions
(Tm, cycle number)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
RANKL ACAGCGCTTCTCAGGAGTTC + 465 60˚C
TGGACGCTAATTTCCTCACC - 30 cycles
OPG TGACCAAGACACCTTGAAGG + 200 60˚C
CTAGTTATAAGCAGCTTATT - 30 cycles
OC TGACAAAGCCTTCATGTCCA + 174 60˚C
TTTGTAGGCGGTCTTCAAGC - 30 cycles
BSP GGGAGGCAGTGACTCTTCAG + 482 60˚C
GTTCCTTCTGCACCTGCTTC - 30 cycles
Coll I ATGACCAGGTTCACCTTTCG + 469 60˚C
AAGAGGCGAGAGAGGTTTCC - 30 cycles
Cbfa1 GGACCGTGGTTACCGTCAT + 242 60˚C
ATGCGCCCTAAATCACTGAG - 30 cycles
BMP-2 AGATCTGTACCGCAGGCACT + 458 60˚C
TCTAAATGGGCCACTTCCAC - 30 cycles
RANK AAGATGGTTCCAGAAGACGGT + 350 60˚C
CATAGAGTCAGTTCTGCTCGGA - 30 cycles
TRAP AAATCACTCTTTAAGACCAG + 316 60˚C
TTATTGAATAGCAGTGACAG - 30 cycles
CTR CTGCTCCTAGTGAGCCCAAC + 444 61˚C
AGTGAGGAACAGCTAACGAC - 40 cycles
Cat K GGGCCAGGATGAAAGTTGTA + 324 60˚C
CCGAGCCAAGAGAGCATATC - 24 cycles
18S TCAAGAACGAAAGTCGGAGGTTCG + 462 62˚C
TTATTGCTCAATCTCGGGTGGCTG - 27 cycles
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aPrimers are presented in a 5' to 3' orientation for the coding strand (+) and 3' to 5' for the non-coding strand (-). The product size generated
by RT-PCR is indicated together with the experimental conditions used (Tm and cycle number corresponding to the linear part of the
amplification curve used to quantify the messages versus the 18S signal, determined in the same way). All the primers are against mouse
molecules, except for RANKL (rat).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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cells were lysed in ice-cold buffer (NaCl 150 mM, Tris 50 mM,
Nonidet P-40 1%, sodium deoxycholate 0.25%, NaF 1 mM,
NaVO4 1 mM, leupeptine 10 mg/ml, aprotinin 10 mg/ml,
PMSF 0.5mM, glycerol 10%). The same amounts of proteins
were resolved on 10% SDS-polyacrylamide gel electro-
phoresis (PAGE), and transferred to a polyvinydilene fluorure
(PVDF) membrane (Millipore, Saint-Quentin en Yvelines,
France). After washing twice with 0.05% Tween-20/PBS, the
membrane was incubated in a saturating solution (0.05%
Tween-20/3% BSA/PBS) for 30 min at room temperature
with appropriate antibodies. The levels of phosphorylated
and total forms of ERK1/2, IκB and p38 were detected by
respective specific antibodies (Ozyme, Saint-Quentin en
Yvelines, France, and R&D) and revealed using the BM
Chemiluminescence Western Blotting substrate (Roche
Applied Science, USA). In another set of experiments, POS-1
cells were cultured in the presence of 25 μM UO 126 (Cal-
biochem Merck, Fontenay-aux-Roses, France), a synthetic
inhibitor of the ERK pathway to confirm the involvement of
the ERK signalling pathway in RANKL-induced biological
activity.
BMP-2 quantification. ELISA assay was used to quantify
BMP-2 levels in culture supernatants of POS-1 cells treated
or not with increasing concentrations of RANKL. Experiments
were realized using the Human/Mouse/Rat BMP-2 Quantikine
ELISA kit (R&D Systems) according to the supplier's
recommendations.
Caspase activity. POS-1 cells (2x104) grown in 24-well
plates were treated with 1-100 ng/ml hBMP-2 for 24-72 h,
washed once with PBS and lysed with 50 μl of RIPA-buffer
for 30 min. The cells were then scraped off and the protein
amount was quantified using the BCA (bicinchominic acid +
Copper II sulfate) test (Pierce Chemical Co., Rockford, IL,
USA). Caspase-3 activity was assessed on 10 μl of cell lysate
with the CaspACE™ assay kit (Promega, Madison, WI,
USA) following the manufacturer's recommendations. Cells
treated with UV light for 30 sec, 24 h before harvesting, were
used as a positive control for caspase activity.
In vivo characterization of osteosarcoma induced by POS-1
cell inoculation. Four-week-old male C3H/He mice (IFFA-
CREDO, L'Arbresle, France) were housed under pathogen-
free conditions at the Experimental Therapy Unit (Medicine
Faculty of Nantes, France), in accordance with the institutional
guidelines of the French Ethical Committee and under the
supervision of authorized investigators. POS-1 cells (2x106)
were inoculated s.c. in the hind footpad of the mice. A tumor
develops at the site of injection within three weeks that can
be transplanted as a small fragment (2x2x2 mm3) in contact
with the femora, leading to the development of a primary
tumor and pulmonary metastases in three weeks. The tumor
was then characterized by micro-architectural studies.
Micro-architectural quantification. Analysis of architectural
parameters was performed using the high resolution X-ray
micro-CT system for small animal imaging SkyScan-1072
(SkyScan, Aartselaar, Belgium). Relative volume (BV/TV)
of the femora [total bone (cortical + trabecular) or trabecular
bone] was quantified in the osteosarcoma group and compared
to that of control mice.
Statistical analyses. Statistical evaluation of the in vitro
proliferation data was performed by the ANOVA test.
Results with p<0.05 were considered significant.
Results
Characterization of osteosarcoma induced by POS-1 cell
injection. After injection of 2x106 POS-1 cells in the hind
footpad of C3H/He mice, a primary tumor develops locally
within approximately 21 days. This tumor can be re-grafted
in contact with the femora, to see whether the primary tumor
exhibits rather osteocondensant or osteolytic features. The
tumor develops locally within two weeks. The mice were
sacrificed 28 days post-implantation, and the femora were
harvested and analysed for their microarchitectural parameters.
The results presented in Fig. 1 demonstrate that the POS-1-
induced osteosarcoma is osteolytic as it reduces the cortical
thickness and dramatically diminishes the relative trabecular
bone volume, as quantified by BV/TV = 0.106 versus 0.27
for the control (-61%, p<0.005) and total bone volume
(BV/TV = 0.42 versus 0.61 for the control, -32%, p<0.005).
POS-1 cells' characterization in vitro. POS-1 cells exhibit an
undifferentiated phenotype, with expression of both osteo-
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Figure 1. Micro-CT scans of mouse femora 4 weeks after implantation with
POS-1 osteosarcoma as compared to controls. A, Hemi-sagittal sections of
control (CT) and osteosarcoma (POS-1) femora are shown. B, Quanti-
fication of relative bone volume (BV/TV) of total and trabecular bone
compared between controls (CT) and osteosarcoma-bearing mice (POS-1).
***p<0.005.
Wittrant 16_8  9/12/05  10:42  Page 264
blastic and osteoclastic markers. Mature osteoblasts are
characterised by the expression of phenotypic markers,
including Coll I, OC, BSP, BMP-2, OPG, RANKL, and the
transcription factor Cbfa1. The constant positive expressions
of these markers were confirmed in the mouse osteoblasts
tested in this study (Fig. 2). In comparison, semi-quantitative
RT-PCR analysis showed that POS-1 cells do not express
several osteoblastic markers, such as BMP-2, OC, BSP, Coll I
and RANKL. However, the expression of Cbfa1 and OPG
transcripts was still observed (Fig. 2). As osteosarcoma may
be heterogeneous in its cell origin and composition, the
expression of other markers was analysed, including osteo-
clastic cathepsin K, TRAP, CTR and RANK. Interestingly,
POS-1 cells expressed Cat K, TRAP and RANK, but not
CTR, which represents one of the most specific osteoclastic
markers (Fig. 2). It can be concluded that POS-1 cells exhibit
an undifferentiated phenotype, expressing markers from both
osteoblastic and osteoclastic lineages.
POS-1 cells' biological activity in vitro. In addition to their
phenotype, POS-1 cells were assessed for their capacity to
demonstrate alkaline phosphatase activity and to induce
mineralization nodules in vitro. Results presented in Fig. 3A
show that POS-1 cells did not demonstrate any alkaline
phosphatase activity as compared to primary osteoblasts.
Bone marrow cells (BMC) isolated from C3H mice contain
osteoblastic cell precursors that can differentiate into mature
osteoblasts when cultured with dexamethasone (12). Both cell
types were incubated with ascorbic acid, dexamethasone and
Na-ß-glycerophosphate or not. After 21 days of culture, the
results of alizarin red staining revealed that POS-1 cells were
not able to form mineralization nodules in the presence of
ß-glycerophosphate, whereas BMC showed marked mine-
ralization nodules (Fig. 3B). Moreover, the nodule formation
induced in BMC alone was totally inhibited when POS-1 cells
were co-cultured with bone marrow cells (not shown).
RANKL inhibits cell proliferation and induces BMP-2
expression in osteosarcoma POS-1 cells. As POS-1 cells
express RANK, RANKL-induced biological activities were
assayed to determine whether the receptor RANK is functional
on osteosarcoma cells and could mediate biological activity.
First, the effects of RANKL were studied on POS-1 cell
proliferation after 72 h of culture. Using an XTT-based method,
1-200 ng/ml hRANKL decreased POS-1 cell proliferation in
the presence of 0.5% inactivated FCS, the maximal effect
being observed at 100 ng/ml (-31%, p=0.003, Fig. 4). In
parallel, the effects of RANKL were studied on POS-1 cell
phenotype modulation by the analysis of osteoblastic and
osteoclastic marker expression by semi-quantitative RT-PCR.
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Figure 2. Bone marker expressed by POS-1 cells in vitro, as compared to mouse primary osteoblasts (OB) and mouse RAW 264.7 cells differentiated in
osteoclast-like cells (RAW). The expression of several bone parameters, among them receptor activator of NF-κB ligand (RANKL), osteoprotegerin (OPG),
osteocalcin (OC), Bone SialoProtein (BSP), type I collagen (Coll I), bone morphogenetic protein-2 (BMP-2), RANK, tartrate resistant acid phosphatase
(TRAP), cathepsin K (Cat K), Core binding factor ·1 (Cbfa1) and calcitonin receptor (CTR) was analysed in POS-1 cells by semi-quantitative RT-PCR
according to the conditions described in Table I, and compared to osteoblasts or RAW 264.7 cells.
Figure 3. In vitro characterization of osteogenic properties of POS-1 cells.
A, alkaline phosphatase activity in cell lysates of POS-1 cells and primary
mouse osteoblasts (OBs) was performed using p-nitrophenyl phosphate as
a substrate and corrected for protein content. The results are presented as
the OD value measured at 405 nm per μg of protein per hour.***p<0.005.
B, mineralized nodule formation in POS-1 cells. POS-1 cells and bone
marrow cells (BMC) were cultured in a medium containing 50 μg/ml ascorbic
acid, 10 mM Na ß-glycerophosphate, 10-8 M dexamethasone for 21 days.
Typical alizarin red-S+ nodules were observed in phase contrast microscopy.
Magnification x200.
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Whereas POS-1 cells did not express BMP-2 at the mRNA
level (Fig. 2), the induction of the BMP-2 transcripts was
observed when these cells were cultured in the presence of
50 ng/ml hRANKL for 6 h with a maximal effect at 100 and
200 ng/ml (Fig. 5A). The RANKL-induced BMP-2 mRNA
expression was then confirmed at the protein level by ELISA,
with a dose-dependent augmentation of BMP-2 in the super-
natant of POS-1 treated with 50, 100 and 200 ng/ml RANKL
(respectively 1.83, 12.66 and 19.05 pg/ml; Fig. 5B). The
expression of other bone markers was not significantly modified
by RANKL treatment (not shown). The ability of RANKL to
induce mineralization nodules was further tested in vitro to
ascertain whether this factor may induce other activities in
POS-1 cells related to enhanced osteogenic potential. The
results revealed no induction of mineralization nodules in
POS-1 cells (not shown). 
RANKL-induced BMP-2 expression depends on ERK signalling
pathways. As RANKL was shown to induce biological
activities in POS-1 cells, Western blot analysis was performed
to determine the signalling pathways involved in these effects.
p38, ERK 1/2 and IκB, the three most reported signalling
pathways for RANKL were analysed (13). The results revealed
a specific induction of the phosphorylated ERK 1/2 form
after 5-, 10- and 15-min incubation with 100 ng/ml hRANKL
(Fig. 6), as compared to the total protein (not shown). The
phosphorylation signal then returned to basal level after an
incubation period of 30 min in the presence of RANKL. A
weaker induction of IκB and p38 phosphorylations was also
observed after 5 and 10-15 min of incubation with hRANKL
respectively (Fig. 6). As ERK seemed to be the major trans-
duction pathway activated by RANKL in POS-1 cells, the
effect of a synthetic ERK inhibitor, UO 126, has been studied
in the RANKL-induced BMP-2 expression. The results
showed a specific blockade of RANKL-induced BMP-2
expression in the presence of 25 μM UO 126 (Fig. 5A). 
Collectively, these results demonstrate that soluble
RANKL acts on POS-1 cells by inducing BMP-2 mRNA and
protein expression through the ERK-dependent signalling
pathway.
RANKL-induced BMP-2 expression has no effect on POS-1
cell behaviour in vitro. To determine whether RANKL-
induced BMP-2 expression may alter POS-1 cell behaviour,
the effects of hBMP-2 (1-100 ng/ml) were assessed in vitro
by proliferation test, caspase-3 activation or alkaline phos-
phatase activity. Using the XTT-based method, 1-100 ng/ml
hBMP-2 did not significantly modify the POS-1 cell pro-
liferation (not shown). As this factor has been described as
promoting osteoblast cell death (14), we analysed the effects
of hBMP-2 on caspase-3 activity in POS-1 cells. The results
showed a weak up-regulation of caspase-3 activity in the
presence of 10 and 50 ng/ml BMP-2 for 72 h, which was not
significant (+5.8% and 5.9% respectively, not shown). To
see whether BMP-2 may modify POS-1 cell biological
activity, alkaline phosphatase activity was studied in the
presence of 1-100 ng/ml hBMP-2 for 24-72 h. No induction
of alkaline phosphatase activity could be detected in POS-1
cells in the presence of BMP-2 (not shown), as observed in
the presence of RANKL (Fig. 2). 
RANKL-induced BMP-2 expression in osteosarcoma POS-1
cells is RANK-dependent. To demonstrate that cell surface
RANK expressed by POS-1 cells is involved in the RANKL-
induced BMP-2 expression, we blocked the RANKL activity
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Figure 4. Effects of soluble human RANKL on POS-1 cell proliferation
in vitro. POS-1 cells were seeded in a 96-well plate and cultured for 72 h in
RPMI-1640 medium supplemented with 0.5% heat-inactivated serum in the
absence or presence of human soluble RANKL at the indicated concentrations.
Proliferation was measured using the XTT quick proliferation kit as described
in Materials and methods. Changes in absorbance at 490 nm were measured
and results are presented as percentage of untreated cell proliferation.
*p<0.05, ***p<0.005.
Figure 5. RANKL induces BMP-2 expression in POS-1 cells. A, relative
BMP-2 mRNA levels were measured by semi-quantitative RT-PCR in
POS-1 cells treated for 6 h in the presence of increasing concentrations of
human RANKL. In a separate experiment, pOS-1 cells were incubated with
200 ng/ml RANKL in the presence of 25 μM UO 126, a synthetic inhibitor
of the ERK pathway. B, ELISA assay was used to quantify BMP-2 levels
in culture supernatants of POS-1 cells treated or not with increasing
concentrations of RANKL for 24 h. ***p<0.005.
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with an excess of soluble RANK by preincubating 100 ng/ml
hRANKL with increasing concentrations of human RANK
before adding to POS-1 cells. The results presented in Fig. 7
showed a complete inhibition of RANKL-induced BMP-2
expression in the presence of a two-fold molar excess of
soluble hRANK.
Discussion
A comprehensive multidisciplinary approach has transformed
osteosarcoma from a disease with a modest long-term
survival to one in which 50-70% of patients will be cured.
Unfortunately, some groups of patients who present with
overt metastatic disease, patients with tumors that recur
after treatment or that show low degrees of necrosis after
administration of chemotherapy, remain at high risk of
eventual relapse and continue to have an unsatisfactory out-
come. These patients may benefit from future investigations
into novel agents, such as biological response modifiers,
anti-angiogenesis factors or growth receptor modulation.
There is an obvious need for an adequate model for the study
of osteosarcoma pathophysiology and to investigate important
problems related to the therapeutics of human bone tumors.
Permanent osteosarcoma cell lines represent an important
tool for the study of primary bone tumors. The POS-1 cell
line is derived from osteosarcoma which developed
spontaneously in C3H mice and parallels with humans clinical
data, leading to spontaneous metastasis to the lungs (10).
This experimental model was used in the present study to
evaluate cellular characteristics in vitro and then correlate
them with the in vivo comportment of the tumor. Conventional
osteosarcomas are classified as fibroblastic, chondroblastic
or, more often, osteoblastic, depending on the predominant
cellular component. However, Narita et al demonstrated that
several tumor cell lines can loose some of their properties
when cultured for a long time in vitro (9). Another study
from Yoshikawa et al demonstrated that HMOS-1, a human
mandibular osteosarcoma cell line with an osteoblastic
phenotype, could induce osteoid formation and ALP activity
but did not express collagen I (15). Taking advantage of our
osteosarcoma model, both at the in vitro and in vivo level,
we wanted to characterize these cells in vitro in relation with
the in vivo behavior of the tumor. In our model, POS-1
osteosarcoma cells express very few osteoblastic markers:
OPG and the transcription factor, Cbfa1, predominantly
described in cells of the osteoblast lineage (16), but not
osteocalcin, Bone SialoProtein, BMP-2 or RANKL, and they
show no ALP activity. In fact, POS-1 osteosarcoma cells
exhibit an undifferentiated phenotype. This is in agreement
with the well-described characteristics of tumor cells showing
an undifferentiated state associated with a high proliferative
capacity, as POS-1 cells were shown to highly proliferate
in vitro. Moreover, these tumor cells express specific tumor
antigens, such as SART3 (not shown), and still exert tumori-
genicity as they induce pulmonary metastatic lesions when
re-injected into mice, and they also induce bone destruction
in vivo contiguously to the tumor itself. It appears, therefore,
that osteosarcoma POS-1 cells in culture express an undiffer-
entiated phenotype but keep their capacity to induce tumor
growth and bone destruction in vivo. In humans, osteosarcomas
frequently penetrate and destroy the cortex of the bone and
extend into the surrounding soft tissue. The unifying histo-
logical feature present in all types and subtypes of OS is the
presence of malignant osteoid produced by the neoplastic
cells (2). As POS-1 cells express some ‘osteoclast’ markers
in vitro (TRAP, Cat K and RANK) and induce bone destruction
in vivo, one can suggest that mouse POS-1 osteosarcoma is
more osteolytic than osteosclerotic. It can be hypothesized
that POS-1 cells can induce osteolytic lesions, as they express
cathepsin K and MMP-9 mRNA, two major enzymes involved
in bone destruction (17).
However, the expression of TRAP and RANK is not
restricted to osteoclasts as TRAP has been already described
in osteoblast-like cells (18) including osteosarcoma (19).
RANK expression has been described in osteosarcoma-derived
cell lines (20) together with bone marrow stromal cells and
osteoblasts (21). Cathepsin K, a cysteine protease expressed
by osteoclasts, appears to be essential for osteoclast-mediated
collagen type-I degradation (22). Cathepsin K is also expressed
in breast cancer cells (23), and Brubaker et al have recently
detected cathepsin K and its proteolytic activity in prostate
cancer tissue and cell lines (24). Therefore, it can be hypo-
thesized that cathepsin K expressed directly by osteosarcoma
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Figure 6. RANKL induces signal transduction pathways in POS-1 cells. At
70-80% confluence, pOS-1 cells were serum-starved for 24 h and then
incubated for 1, 2, 5, 10, 15 and 30 min. in the absence or presence of 100 ng/
ml human RANKL. Aliquots of whole cell lysates were analysed by
immunoblotting for phospho-ERK 1/2phospho IκB and phospho p38.
Figure 7. RANKL-induced BMP-2 expression in POS-1 cells is inhibited by
soluble RANK. At 70-80% confluence, pOS-1 cells were treated for 6 h
with 100 ng/ml hRANKL that was first pre-incubated for 1 h with 400 ng/ml
human soluble RANK (2-fold molar excess). Relative BMP-2 mRNA levels
were measured by semi-quantitative RT-PCR and corrected with the 18S
mRNA levels. A representative experiment is shown. 
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cells participates in the development of osteolytic lesions
observed in our POS-1 model.
The OPG/RANK/RANKL triad is an important therapeutic
axis in pathologies involving a dysregulation in bone re-
modelling, including tumor-associated osteolysis (4). A
number of studies provide evidence for the direct production
of RANKL by tumor cells themselves, as reported in multiple
myeloma (25), prostate cancer (26), carcinoma cell lines (6)
or human neuroblastoma (27). RANKL can then bind to its
cognate receptor, RANK, at the surface of osteoclast precursors
acting directly on osteoclast differentiation and activation. In
the present POS-1 osteosarcoma model, POS-1 cells express
RANK, not RANKL. RANK is known to be predominantly
present at the surface of osteoclasts and some immune cells
(28), but its expression has also been revealed in marrow
stromal cells and osteoblasts and was strongly up-regulated
when activated by T-cell conditioned medium (21). Another
publication from Miyamoto et al reported that human
osteosarcoma-derived cell lines expressed both RANK and
RANKL mRNAs but the functionality of the receptor, RANK,
was not investigated (20). However, the presence of a
functional receptor, RANK, at the surface of cancer cells is
in agreement with the results of Tometsko et al who recently
reported the direct effects of RANKL on RANK-expressing
human breast cancer cells, MDA-MB-231, and prostate PC3
(29). They demonstrated that RANKL treatment of both
MDA-231 and PC3 cells led to the activation of signal trans-
duction pathways (p38 MAPK, p42/44 MAPK, NF-κB) and
upregulated the expression of 194 mRNA as assessed by
micro-array. From these data, we can hypothesize that, while
neither cell line (MDA-231, PC3 and POS-1) expresses
RANKL in vitro, it is probable that the locally increased
RANKL within the bone microenvironment could activate
tumor cell-expressed RANK in a paracrine manner.
In our experimental model, RANKL decreased POS-1
cell proliferation and induced the expression of BMP-2
through its receptor, RANK, expressed on osteosarcoma
cells. The in vitro induction of BMP-2 by RANKL does not
reflect an enhancement of the osteogenic properties of the
cells, as mineralization was not induced by RANKL, nor
expression of other bone anabolic molecules. BMPs are a
group of related proteins which are capable of inducing the
formation of cartilage and bone, but are now regarded as
multifunctional cytokines. A study by Hay et al (14) demon-
strated that BMP-2 promoted apoptosis in primary human
calvaria osteoblasts by increasing the Bax/Bcl-2 ratio, the
release of cytochrome c to the cytosol and caspase-9, -3, -6
and -7 activity. As BMP-2 induces apoptosis in myeloma
cell lines and primary samples from patients with multiple
myeloma in vitro, it has been suggested that this cytokine
may have the potential to be a novel therapeutic agent for the
treatment of patients with multiple myeloma (30). As BMP-2's
receptors have been described on several cancer cell lines, its
effects as an anticancer drug is now emerging (31). However,
in the present study, BMP-2 did not induce POS-1 cell
apoptosis nor modulate POS-1 cell proliferation. Therefore,
further study is needed to explore the potential biological
activity of BMP-2 in osteosarcoma.
The RANK signalling mechanisms involved in RANKL
responses have been well described and include the recruitment
of TNF receptor-associated factor proteins, the activation of
transcription factors (NF-κB, AP-1, and NFAT2), the cascades
of mitogen-activated protein kinases (ERK, JNK, and p38),
and the induction of Src- and phosphatidylinositol 3-kinase-
dependent Akt activation (13). In the present study, RANKL
predominantly induced ERK phosphorylation with a weak
activation of NF-κB and p38 signalling pathways. As synthetic
inhibition of the ERK pathway totally blocked the RANKL-
induced BMP-2 expression in POS-1 cells, this signal trans-
duction pathway seemed to be the major pathway activated
by RANKL through its receptor, RANK, at the surface of
osteosarcoma cells, whereas NF-κB and p38 pathways were
less involved. 
This study describes for the first time the presence of a
functional receptor RANK at the surface of osteosarcoma
cells, that may mediate the establishment of osteolytic lesions
induced by the tumor in vivo. Targeting RANKL/RANK
interaction by the use of OPG or soluble RANK may offer
new therapeutic approaches for osteosarcoma, as it has for
other malignant osteolytic pathologies (32).
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